Baseline systolic blood pressure and longitudinal increase in HbA1c levels as predictors of bone mineral density in older men: a 4-year prospective study

Background: Bone mineral density (BMD) is a key determinant of fracture risk and functional decline in older adults. Age-related metabolic and vascular dysregulation may contribute to skeletal vulnerability; however, their predictive value for subsequent BMD levels in older men remains unclear. This study aimed to examine whether baseline metabolic indicators and their 4-year changes can predict BMD measured at follow-up in community-dwelling older men. Methods: In this prospective predictive analysis, 86 men aged 65 years and older underwent assessments of physical characteristics and metabolic syndrome-related indicators at baseline and after 4 years. The BMD of the distal forearm was measured at follow-up using dual-energy X-ray absorptiometry. Multiple linear regression analyses were performed to identify baseline and longitudinal metabolic predictors of follow-up BMD. Results: In the baseline predictor model, higher baseline systolic blood pressure was independently associated with lower BMD at follow-up. In the change-inclusive model, a 4-year increase in hemoglobin A1c (HbA1c) was independently associated with lower BMD at follow-up, whereas baseline HbA1c levels were not predictive. Other metabolic indicators did not show significant associations with follow-up BMD. Conclusions: Baseline systolic blood pressure and longitudinal increases in HbA1c levels were independent predictors of lower BMD measured at follow-up in community-dwelling older men. These findings suggest that commonly assessed metabolic indicators may provide useful predictive information for identifying older men at risk of low BMD, highlighting the importance of vascular and metabolic health in skeletal aging.

Aging; Bone mineral density; Metabolic indicators; HbA1c levels; Hypertension

[1] Ministry of Health, Labour and Welfare. Age of the 100-year life—current state of employment measures for the elderly. 2023. Available at: https://www.mhlw.go.jp/content/10500000/001086776.pdf (Accessed: 05 April 2025).

[2] Ministry of Health, Labour and Welfare. Summary report of comprehensive survey of living conditions 2022. 2023. Available at: https://warp.ndl.go.jp/web/20260317011824/https://www.mhlw.go.jp/english/database/db-hss/dl/report_gaikyo_2022.pdf (Accessed: 11 March 2026).

[3] Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. The BMJ. 1996; 312: 1254–1259.

[4] Yoshimura N, Iidaka T, Horii C, Muraki S, Oka H, Kawaguchi H, et al. Trends in osteoporosis prevalence over a 10-year period in Japan: the ROAD study 2005–2015. Journal of Bone and Mineral Metabolism. 2022; 40: 829–838.

[5] Pramusita A, Kitaura H, Ohori F, Noguchi T, Marahleh A, Nara Y, et al. Salt-sensitive hypertension induces osteoclastogenesis and bone resorption via upregulation of angiotensin II type 1 receptor expression in osteoblasts. Frontiers in Cell and Developmental Biology. 2022; 10: 816764.

[6] Diamond TH, Thornley SW, Sekel R, Smerdely P. Hip fracture in elderly men: prognostic factors and outcomes. The Medical Journal of Australia. 1997; 167: 412–415.

[7] Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. The Lancet. 1999; 353: 878–882.

[8] Forsén L, Sogaard AJ, Meyer HE, Edna T, Kopjar B. Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporosis International. 1999; 10: 73–78.

[9] Palermo A, Tuccinardi D, Defeudis G, Watanabe M, D’Onofrio L, Lauria Pantano A, et al. BMI and BMD: the potential interplay between obesity and bone fragility. International Journal of Environmental Research and Public Health. 2016; 13: 544.

[10] Kang DH, Guo LF, Guo T, Wang Y, Liu T, Feng XY, et al. Association of body composition with bone mineral density in northern Chinese men by different criteria for obesity. Journal of Endocrinological Investigation. 2015; 38: 323–331.

[11] Iwaniec UT, Turner RT. Influence of body weight on bone mass, architecture and turnover. The Journal of Endocrinology. 2016; 230: R115–R130.

[12] Zhang Y, Pu J. The saturation effect of obesity on bone mineral density for older people: the NHANES 2017–2020. Frontiers in Endocrinology. 2022; 13: 883862.

[13] Jiao Y, Sun J, Li Y, Zhao J, Shen J. Association between adiposity and bone mineral density in adults: insights from a national survey analysis. Nutrients. 2023; 15: 3492.

[14] Gkastaris K, Goulis DG, Potoupnis M, Anastasilakis AD, Kapetanos G. Obesity, osteoporosis and bone metabolism. Journal of Musculoskeletal & Neuronal Interactions. 2020; 20: 372–381.

[15] Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporosis International. 2010; 21: 195–214.

[16] Ge W, Jie J, Yao J, Li W, Cheng Y, Lu W. Advanced glycation end products promote osteoporosis by inducing ferroptosis in osteoblasts. Molecular Medicine Reports. 2022; 25: 140.

[17] Nishikawa H, Asai A, Fukunishi S, Nishiguchi S, Higuchi K. Metabolic syndrome and sarcopenia. Nutrients. 2021; 13: 3519.

[18] Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. The Journal of Endocrinology. 2016; 229: R67–R81.

[19] Brotto M, Bonewald L. Bone and muscle: interactions beyond mechanical. Bone. 2015; 80: 109–114.

[20] Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, et al. Assessment of fracture risk. Osteoporosis International. 2005; 16: 581–589.

[21] Bevier WC, Wiswell RA, Pyka G, Kozak KC, Newhall KM, Marcus R. Relationship of body composition, muscle strength, and aerobic capacity to bone mineral density in older men and women. Journal of Bone and Mineral Research. 1989; 4: 421–432.

[22] O’Brien RG, Muller KE. Unified power analysis for t-tests through multivariate hypotheses. In Edwards LK (ed.) Applied analysis of variance in behavioral science (pp. 297–344). 1st edn. Marcel Dekker: New York. 1993.

[23] Nagashima K. A sample size determination tool for the paired t-test. 2023. Available at: https://nshi.jp/contents/js/pairedmean/ (Accessed: 24 November 2025).

[24] Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplantation. 2013; 48: 452–458.

[25] Yang S, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Association between hypertension and fragility fracture: a longitudinal study. Osteoporosis International. 2014; 25: 97–103.

[26] Iki M, Fujita Y, Kouda K, Yura A, Tachiki T, Tamaki J, et al. Hyperglycemic status is associated with an elevated risk of osteoporotic fracture in community-dwelling elderly Japanese men: the Fujiwara-kyo osteoporosis risk in men (FORMEN) cohort study. Bone. 2019; 121: 100–106.

[27] Armutcu F, McCloskey E. Insulin resistance, bone health, and fracture risk. Osteoporosis International. 2024; 35: 1909–1917.

[28] Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporosis International. 2007; 18: 427–444.

[29] Ogata M, Ide R, Takizawa M, Tanaka M, Tetsuo T, Sato A, et al. Association between basal metabolic function and bone metabolism in postmenopausal women with type 2 diabetes. Nutrition. 2015; 31: 1394–1401.

[30] Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P. Pentosidine effects on human osteoblasts in vitro. Annals of the New York Academy of Sciences. 2008; 1126: 166–172.

[31] Hein G, Wiegand R, Lehmann G, Stein G, Franke S. Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology. 2003; 42: 1242–1246.

[32] Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010; 142: 296–308.

[33] Takizawa M, Suzuki K, Matsubayashi T, Kikuyama M, Suzuki H, Takahashi K, et al. Increased bone resorption may play a crucial role in the occurrence of osteopenia in patients with type 2 diabetes: possible involvement of accelerated polyol pathway in its pathogenesis. Diabetes Research and Clinical Practice. 2008; 82: 119–126.

[34] Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. Journal of Bone and Mineral Research. 2009; 24: 702–709.

[35] Saito M, Marumo K. Effects of collagen crosslinking on bone material properties in health and disease. Calcified Tissue International. 2015; 97: 242–261.

[36] Dong Q, Li D, Zhang K, Shi H, Cai M, Li Y, et al. Muscle-bone biochemical crosstalk in osteosarcopenia: focusing on mechanisms and potential therapeutic strategies. The Journal of Endocrinology. 2025; 266: e250234.

[37] Tagliaferri C, Wittrant Y, Davicco MJ, Walrand S, Coxam V. Muscle and bone, two interconnected tissues. Ageing Research Reviews. 2015; 21: 55–70.

[38] Yamamoto M, Sugimoto T. Advanced glycation end products, diabetes, and bone strength. Current Osteoporosis Reports. 2016; 14: 320–326.

[39] Cianferotti L, Brandi ML. Muscle-bone interactions: basic and clinical aspects. Endocrine. 2014; 45: 165–177.

[40] Leong DP, Teo KK, Rangarajan S, Lopez-Jaramillo P, Avezum A III, Orlandini A, et al.; Prospective Urban Rural Epidemiology (PURE) Study Investigators. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. The Lancet. 2015; 386: 266–273.

[41] Bohannon RW. Reference values for the five-times sit-to-stand test: a descriptive meta-analysis of data from elders. Perceptual and Motor Skills. 2006; 103: 215–222.

[42] Yamagishi S, Maeda S, Matsui T, Ueda S, Fukami K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochimica et Biophysica Acta. 2012; 1820: 663–671.

[43] Schwartz AV. Diabetes mellitus: does it affect bone? Calcified Tissue International. 2003; 73: 515–519.

[44] Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. Endocrinology and Metabolism Clinics of North America. 2005; 34: 1015–1030.

[45] Ministry of Health, Labour and Welfare. Public welfare statistics handbook. Mean of height, the weight, sex, annual× age distinction. 2017. Available at: https://www.mhlw.go.jp/toukei/youran/indexyk_2_1.html (Accessed: 05 April 2025).